The Lymphoma Academic Research Organisation

This study tested an oral chemotherapy drug (azacitidine) against standard single-drug treatments in 86 adults with a rare type of T-cell lymphoma that had returned or stopped responding to therapy. The goal was to see if the oral drug could delay cancer growth better than the us…

This study tested a drug called obinutuzumab combined with chemotherapy (DHAP) and a stem cell transplant in 86 adults with mantle cell lymphoma, a rare blood cancer. After the transplant, patients received obinutuzumab as maintenance therapy to keep the cancer from coming back. …

This study tested whether a combination of rituximab and lenalidomide works better than the standard rituximab plus chemotherapy for people with untreated follicular lymphoma. About 1,000 participants with advanced disease were enrolled. The goal was to see if the new combo impro…

This study tested a drug called glofitamab in 67 people with lymphoma that did not respond or came back after CAR T-cell therapy. Glofitamab is a bispecific antibody that helps the immune system attack cancer cells. The goal was to see if it could control the disease, not cure it…

This study tested a four-drug combination including pixantrone for adults with aggressive non-Hodgkin lymphoma that had returned or not responded to previous treatments. The main goal was to see if the treatment could shrink or eliminate the cancer, as measured by PET scans. Rese…